AzTrials
AzTrials

Rheumatoid ArthritisMICROPORENCT04056234

Study of the Articular Microbiota in Rheumatoid Arthritis.

An observational study of Rheumatoid Arthritis and Synovial Disorder, run by University Hospital, Bordeaux.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The cause of rheumatoid arthritis (RA) remains unknown, although major advances have been done these last ten years in the comprehension of its pathophysiology. The aim of this study is to described a synovial microbiota specific for rheumatoid arthritis. Read more about this study

Who is it for?
Any age
Conditions the study is for
Rheumatoid Arthritis, Synovial Disorder, Arthrosis
What is being tested?
Joint puncture
Type of treatment
Surgery or procedure
How many people
36 participants
Where
No sites listed yet
Study dates
21 Feb 2012to 22 Feb 2013
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: This is a pilot study. The number of subjets will be 12 RA patients and 6 controls suffering from osteoarthritis.

Who may be able to join

  • patients presenting with RA according to ACR87 and ACR/EULAR 2010 criteria
  • patients presenting with RA anti-citrullinated peptide antibodies positive
  • patients presenting with active RA, characterized by at least one synovitis
  • patients presenting with an arthritis requiring arthrocentesis and synovial fluid collection for diagnostic or therapeutic purpose
  • patients giving agreement to participate to the study and to sign informed consent.

Who cannot join

  • patients suffering from osteoarthritis
  • patients presenting with joint effusion justifying an arthrocentesis and synovial fluid collection for diagnostic of therapeutic purpose
  • patients giving agreement to participate to the study and to sign informed consent
  • Patients presenting with another arthropathy than anti-citrullinated peptide antibodies positive RA or osteoarthritis
  • Patients not requiring arthrocentesis for medical reasons
  • Patients refusing to sign informed consent
  • Patients presenting with understanding problems due to language or cognitive reasons.

About this study

The cause of rheumatoid arthritis (RA) remains unknown, although major advances have been done these last ten years in the comprehension of its pathophysiology.

The aim of this study is to described a synovial microbiota specific for rheumatoid arthritis.

Read the detailed description

The cause of rheumatoid arthritis (RA) remains unknown, although major advances have been done these last ten years in the comprehension of its pathophysiology. One of the most significant discoveries was the post-translational modification of various self-proteins resulting in the replacement of arginine residues by citrulline. This conversion results in modifications of the basic charge of the peptides, of its primary and secondary structure, and the transformed peptides can then bound to some HLA-DR molecules (HLA-DR4, HLA-DR1), that are the best well known genetic factors of rheumatoid arthritis (RA). This leads to immunization to citrullinated peptides in genetically predisposed patients, which is now identified as the most characteristic auto-immun phenomenon of RA. Anti-citrullinated peptide antibodies (ACPA) have become the most relevant biologic test for the diagnosis of RA.

The conversion to citrulline is due to the action of an enzyme, the peptidyl arginine deiminase (PAD). Endogenous PADs have been identified in humans, but their activation needs high concentrations of calcium in the cells that are not physiological. Thus, the activation of self-PADs occurs only in extreme conditions, such as apoptosis, or major stresses resulting from toxic or infectious process. But some bacteria also contain PADs that are involved in their energetic metabolism. Two main factors have yet been identified to lead to citrullination of self-peptides and are now recognized as important environment risk factors for RA: smoking and periodontitis. Periodontitis is the consequence of an infection that is mainly due to Porphyromonas gingivalis, one of the bacteria processing a PAD. These facts reinforce the old hypothesis of an infectious origin of RA.

However, all RA patients are neither smoker nor affected by periodontitis, and many other bacteria have PADs and may be involved in the pathophysiology of RA. Moreover, it has been demonstrated that citrullination process and ACPA production can precede RA for years, while the citrullination and ACPA production are located to a mucous membrane (oral, pulmonary…). How these processes reach the joint remains a mystery.

The hypothesis is that the involved bacteria translocate to the joint, inducing local citrullination of synovial peptides, inflammation and production of ACPA within the joint, and resulting in arthritis.

The aim of this study is to demonstrate this translocation of bacteria in the synovium, and to described a synovial microbiota specific for rheumatoid arthritis .

Pilot study, including only few patients, just to demonstrate the validity of the translocation concept and the performance of the procedures.

Being tested
Joint puncture
Keywords
Translocation, Synovial microbiota
Medical subject headings
Arthritis, Rheumatoid, Osteoarthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Joint punctureProcedure or surgery

    Patient requiring joint puncture for diagnostic or therapeutic reasons.

Study groups in NCT04056234
Study groupRoleWhat they receive
Rheumatoid arthritis groupPatients with rheumatoid arthritis
Receives: Procedure: Joint puncture
Control groupPatients with osteoarthritis / joint effusion.
Receives: Procedure: Joint puncture

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Presence of bacterial DNA by 16s PCR

    Detection by 16s PCR of DNA of bacterial origin in synovial fluid specimens

    Measured: At the screening

  2. Presence of a characteristic microbiota

    Research of a characteristic microbiota of rheumatoid arthritis

    Measured: At the screening

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2019
  2. Study start21 Feb 2012
  3. Primary completion22 Feb 2013
  4. Study completion22 Feb 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
36 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04056234
Sponsor's protocol ID
CHU BX 2011/12
Acronym
MICROPORE
Status last verified
Aug 2019
First submitted
12 Aug 2019
Last updated
14 Aug 2019
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Rheumatoid Arthritis and Synovial Disorder, run by University Hospital, Bordeaux.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Presence of bacterial DNA by 16s PCR (time frame: At the screening). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in